Based on these mechanisms, targeted inhibition strategies against key nodes in DDR pathways (such as CHK1/CDK1) and the CSCs microenvironment offer novel therapeutic approaches for overcoming tumor resistance. The gene discussed is CDK1; the disease is neoplasm.